Results 11 to 20 of about 2,238 (188)

Clinical characteristics and outcomes of pregnancies at-risk of hemolytic disease of the fetus and newborn in Sweden, Finland, and Denmark: a population-based register studyAJOG Global Reports at a Glance

open access: yesAJOG Global Reports
Background: Red blood cell (RBC) alloimmunization is an immune response where the maternal immune system produces antibodies against fetal RBCs, which can lead to hemolytic disease of the fetus and newborn (HDFN).
Kelvin H.M. Kwok, PhD   +9 more
doaj   +2 more sources

Hemolytic disease of fetus and newborn due to maternal red blood cell alloantibodies in the Malay population

open access: yesAsian Journal of Transfusion Science, 2014
Background: Maternal red blood cell (RBC) alloimmunization may lead to production of harmful antibodies that result in hemolytic disease of fetus and newborn (HDFN).
Mohd Nazri Hassan   +5 more
doaj   +2 more sources

Mapping obstetric biobanks: A scoping review highlighting gaps in the study of alloimmunized pregnancies [PDF]

open access: yesTransfusion, Volume 66, Issue 11, Page 2373-2384, November 2026.
Abstract Background Maternal red cell alloimmunization can cause hemolytic disease of the fetus and newborn (HDFN), yet prediction of disease severity remains limited. Biobanks that link pregnancy biospecimens with clinical and laboratory data could accelerate translational research; however, the landscape of relevant obstetric biobanks has not been ...
Orlin Chowdhury   +10 more
wiley   +2 more sources

Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn [PDF]

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is under evaluation for severe hemolytic disease of the fetus and newborn (HDFN). In the Phase 2 UNITY trial, weekly intravenous antenatal treatment with nipocalimab at dose regimens of 30 and 45 mg/kg prevented fetal anemia requiring intrauterine transfusion (IUT) in 54% of high‐risk ...
Jie Zhou   +8 more
wiley   +2 more sources

Health Care Use and Recurrence Rate in Hemolytic Disease of the Fetus and Newborn: Retrospective Cohort Study [PDF]

open access: yesJMIR Pediatrics and Parenting
BackgroundHemolytic disease of the fetus and newborn (HDFN) is a life-threatening condition resulting from maternal-fetal erythrocyte antigen incompatibility.
Nehaa Khadka   +9 more
doaj   +2 more sources

Understanding Patient Perspectives and Experiences in Severe Hemolytic Disease of the Fetus and Newborn: Insights from Qualitative Interviews [PDF]

open access: yesAmerican Journal of Perinatology Reports
Objective Maternal red cell alloimmunization is a rare pregnancy condition that can cause hemolytic disease of the fetus and newborn (HDFN), which can be serious and fatal. As subsequent alloimmunized pregnancies carry HDFN risk, families’
Adele Barlassina   +6 more
doaj   +2 more sources

A distinctive RhD serologic phenotype expressed by p.Glu233Lys RHD alleles DV type 5 and DAU4 in microplate agglutination RhD typing [PDF]

open access: yesTransfusion, Volume 66, Issue 11, Page 2116-2122, November 2026.
Abstract Background In patients with variant RhD phenotypes, serologic reactions for partial RHD genotypes are indistinguishable from other variants. Study Design and Methods In two US transfusion services, patients were typed for RhD by automated microplate RhD typing (Werfen, Norcross, GA) using two directly agglutinating IgM anti‐D reagents, MS201 ...
Vidyadhari Karne   +4 more
wiley   +2 more sources

Synthesis, Characterization, In Vitro and In Silico Investigation of Azo‐Based Co(III), Zn(II), and Pd(II) Complexes Against Human Leukemia [PDF]

open access: yesChemistry &Biodiversity, Volume 23, Issue 9, September 2026.
A novel azo ligand (IDB) and its Co(III), Zn(II), and Pd(II) complexes were synthesized and characterized. The Pd(II) complex demonstrated potent activity against HL‐60 leukemia cells, modulated oxidative stress markers (MDA, CAT), and showed strong binding affinity (−6.6367 kcal/mol) to the Aurora kinase enzyme in molecular docking studies.
Yareeb J. Sahar   +2 more
wiley   +2 more sources

Maternal health, neonatology and perinatology towards a standardized outcome set for clinical trials in Hemolytic Disease of the Fetus and Newborn (HDFN): preliminary findings from two European advisory boards [PDF]

open access: yesMaternal Health, Neonatology and Perinatology
Hemolytic Disease of the Fetus and Newborn (HDFN) remains a serious perinatal condition worldwide despite major advances in antenatal and postnatal care.
Enrico Lopriore   +6 more
doaj   +2 more sources

HAEMOLYTIC DISEASE OF THE FETUS AND NEWBORN (HDFN) – CASE REPORT [PDF]

open access: yesZdravniški Vestnik, 2003
Background. Hemolytic disease of the fetus and newborn (HDFN) develops because of the passage of maternal erythrocyte alloantibodies through the placenta. These antibodies cause a reduction of the erythrocyte life span in the fetus and newborn. This severe form of the disease is most commonly caused by anti-D antibodies.
Irena Bricl   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy